0001567619-20-018008.txt : 20201020 0001567619-20-018008.hdr.sgml : 20201020 20201020165822 ACCESSION NUMBER: 0001567619-20-018008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201020 FILED AS OF DATE: 20201020 DATE AS OF CHANGE: 20201020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Venture Capital VI, L.P. CENTRAL INDEX KEY: 0001687880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 201248793 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Vantage I, L.P. CENTRAL INDEX KEY: 0001765253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 201248794 BUSINESS ADDRESS: STREET 1: ONE SANSOME, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER NAME: FORMER CONFORMED NAME: Versant Opportunity Fund I, L.P. DATE OF NAME CHANGE: 20190117 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2020-10-20 1 0001799448 Aligos Therapeutics, Inc. ALGS 0001687880 Versant Venture Capital VI, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001765253 Versant Vantage I, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 Common Stock 2020-10-20 4 C 0 2145991 A 2145991 D Common Stock 2020-10-20 4 C 0 198839 A 2344830 D Common Stock 2020-10-20 4 C 0 85065 A 2429895 D Common Stock 2020-10-20 4 C 0 463959 A 463959 I See footnote Common Stock 2020-10-20 4 C 0 198485 A 662444 I See footnote Common Stock 2020-10-20 4 P 0 200000 15 A 862444 I See footnote Series A Preferred Stock 2020-10-20 4 C 0 2145991 0.00 D Common Stock 2145991 0 D Series B-1 Preferred Stock 2020-10-20 4 C 0 198839 0.00 D Common Stock 198839 0 D Series B-1 Preferred Stock 2020-10-20 4 C 0 463959 0.00 D Common Stock 463959 0 I See footnote Series B-2 Preferred Stock 2020-10-20 4 C 0 85065 0.00 D Common Stock 85065 0 D Series B-2 Preferred Stock 2020-10-20 4 C 0 198485 0.00 D Common Stock 198485 0 I See footnote Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Thomas Woiwode Ph.D. is a managing director of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the Issuer. These securities are held of record by by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Thomas Woiwode Ph.D. is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I and disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. A Form 4 is being filed separately by Dr. Woiwode in his capacity as a Director of the issuer. /s/ Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC By: Robin L. Praeger Its: Managing Director /s/ Versant Vantage I, LP By: Versant Vantage I GP, L.P. Its: General Partner By: Versant Vantage I GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director See Remarks 2020-10-20